دورية أكاديمية
أعرض في EDS

Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.

التفاصيل البيبلوغرافية
العنوان: Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
المؤلفون: Paly JJ; Departments of Radiation Oncology., Egleston BL; Biostatistics., Wong JK; Departments of Radiation Oncology., Burbure N; Departments of Radiation Oncology., Sobczak ML; Departments of Radiation Oncology., Hayes SB; Departments of Radiation Oncology., Chen DYT; Urology, Fox Chase Cancer Center, Philadelphia, PA., Horwitz EM; Departments of Radiation Oncology., Hallman MA; Departments of Radiation Oncology.
المصدر: American journal of clinical oncology [Am J Clin Oncol] 2021 Apr 01; Vol. 44 (4), pp. 131-136.
نوع المنشور: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8207754 Publication Model: Print Cited Medium: Internet ISSN: 1537-453X (Electronic) Linking ISSN: 02773732 NLM ISO Abbreviation: Am J Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: New York, N.Y. : Masson Pub. USA, c1982-
مواضيع طبية MeSH: Patient Reported Outcome Measures* , Quality of Life*, Adenocarcinoma/*radiotherapy , Brachytherapy/*psychology , Prostatic Neoplasms/*radiotherapy , Radiosurgery/*psychology, Adenocarcinoma/psychology ; Adult ; Aged ; Aged, 80 and over ; Brachytherapy/methods ; Dose Fractionation, Radiation ; Humans ; Male ; Middle Aged ; Prospective Studies ; Prostatic Neoplasms/psychology ; Radiation Injuries/etiology ; Radiation Injuries/psychology ; Radiotherapy Dosage ; Severity of Illness Index ; Sexual Dysfunction, Physiological/etiology ; Sexual Dysfunction, Physiological/psychology ; Surveys and Questionnaires ; Treatment Outcome ; Urination Disorders/etiology ; Urination Disorders/psychology
مستخلص: Purpose: We sought to compare changes in patient-reported quality of life (PRQOL) following stereotactic body radiation therapy (SBRT), high dose rate (HDR), and low dose rate (LDR) brachytherapy for prostate cancer.
Materials and Methods: International Prostate Symptom Score (IPSS), Sexual Health Inventory For Men (SHIM), and Expanded Prostate cancer Index Composite Short Form (EPIC-26) were prospectively collected for men with low/intermediate-risk cancer treated at a single institution. We used Generalized Estimating Equations to identify associations between variables and early (3 to 6 mo) or late (1 to 2 y) PRQOL scores. Minimally important differences (MID) were compared with assess clinical relevance.
Results: A total of 342 LDR, 159 HDR, and 112 SBRT patients treated from 2001 to 2018 were eligible. Gleason score, PSA, and age were lower among LDR patients compared with HDR/SBRT. Unadjusted baseline IPSS score was similar among all groups. Adjusted IPSS worsened at all time points compared with baseline after LDR/HDR. At early/late time points, rates of IPSS MID after LDR were higher compared to HDR/SBRT. There were no IPSS differences between SBRT and HDR. All modalities showed early and late SHIM worsening. There were no temporal differences in SHIM between SBRT and brachytherapy. There were no differences in EPIC subdomains between HDR and SBRT. Bowel symptoms worsened early after SBRT, whereas urinary irritative/obstructive symptoms worsened late after HDR. Among all domains, MID after SBRT and HDR were similar.
Conclusions: In a cohort of patients treated with modern radiotherapy techniques, HDR and SBRT resulted in clinically meaningful improved urinary PRQOL compared with LDR.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
References: Jackson WC, Silva J, Hartman HE, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019;104:778–789.
Patel S, Demanes DJ, Ragab O, et al. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. Brachytherapy. 2017;16:299–305.
Zelefsky MJ, Yamada Y, Pei X, et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology. 2011;77:986–990.
Muralidhar V, Nguyen PL. Maximizing resources in the local treatment of prostate cancer: a summary of cost-effectiveness studies. Urol Oncol. 2017;35:76–85.
Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol. 2018;8:354–360.
Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261.
Morgan TM, Press RH, Cutrell PK, et al. Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. J Contemp Brachytherapy. 2018;10:495–502.
Keyes M, Miller S, Moravan V, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009;73:1023–1032.
King CR, Collins S, Fuller D, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013;87:939–945.
Chang P, Szymanski KM, Dunn RL, et al. Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): development and validation of a practical health-related quality of life instrument for use in the routine clinical care of prostate cancer patients. J Urol. 2011;186:865–872.
Skolarus TA, Dunn RL, Sanda MG, et al. Minimally important difference for the expanded prostate cancer index composite short form. Urology. 2015;85:101–106.
Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol. 1995;154:1770–1774.
Ash D, Bottomley D, Al-Qaisieh B, et al. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol. 2007;84:135–139.
Frank SJ, Pugh TJ, Blanchard P, et al. Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes. Int J Radiat Oncol Biol Phys. 2018;100:374–382.
Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171:1098–1104.
Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13.
Barkati M, Williams SG, Foroudi F, et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial. Int J Radiat Oncol Biol Phys. 2012;82:1889–1896.
Katz A, Ferrer M, Suárez JF. Multicentric Spanish Group of Clinically Localized Prostate Cancer. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer. Radiat Oncol. 2012;7:194–202.
Evans JR, Zhao S, Daignault S, et al. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015;116:179–184.
Boyer MJ, Papagikos MA, Kiteley R, et al. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer. Radiat Oncol. 2017;12:14–22.
Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20:1531–1543.
Stokes WA, Kavanagh BD, Raben D, et al. Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis. Pract Radiat Oncol. 2017;7:270–278.
Laviana AA, Ilg AM, Veruttipong D, et al. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. Cancer. 2016;122:447–455.
Barnes J, Kennedy WR, Fischer-Valuck BW, et al. Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer. J Contemp Brachytherapy. 2019;11:320–328.
Orio PF, Nguyen PL, Buzurovic I, et al. Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training. Int J Radiat Oncol Biol Phys. 2016;96:624–628.
معلومات مُعتمدة: P30 CA006927 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20210212 Date Completed: 20210429 Latest Revision: 20230224
رمز التحديث: 20231215
DOI: 10.1097/COC.0000000000000796
PMID: 33577175
قاعدة البيانات: MEDLINE
الوصف
تدمد:1537-453X
DOI:10.1097/COC.0000000000000796